Head-To-Head Review: Exagen (NASDAQ:XGN) vs. Hims & Hers Health (NYSE:HIMS)

Exagen (NASDAQ:XGN) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Risk and Volatility

Exagen has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500.

Valuation and Earnings

This table compares Exagen and Hims & Hers Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57 million	3.08	-$19.95 million	($0.81)	-10.43
Hims & Hers Health	$2.35 billion	2.80	$128.37 million	($0.63)	-44.79

Hims & Hers Health has higher revenue and earnings than Exagen. Hims & Hers Health is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.2% of Exagen shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Exagen and Hims & Hers Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Exagen and Hims & Hers Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1	0	7	1	2.89
Hims & Hers Health	1	11	3	0	2.13

Exagen presently has a consensus target price of $10.12, indicating a potential upside of 19.84%. Hims & Hers Health has a consensus target price of $32.43, indicating a potential upside of 14.93%. Given Exagen’s stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Hims & Hers Health.

Summary

Hims & Hers Health beats Exagen on 8 of the 15 factors compared between the two stocks.

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.